参考文献(向上滑动查看更多参考文献)[1] Freedman B A , Heller J G . Kummel Disease: A Not-So-Rare Complication of Osteoporotic Vertebral Compression Fractures[J]. Journal of the American Board of Family Medicine, 2009, 22(1):75-78.[2] KummellH.Die rarefizierende ostitis der wirbelkorper[J].Deutsche Med,1895,21:180-181.[3] SteelHH.Kümmell's disease[J].AmJSurg, 1951, 81:161-167.[4]章振林, 金小岚, 夏维波. 原发性骨质疏松症诊疗指南(2017版)要点解读[J]. 中华骨质疏松和骨矿盐疾病杂志, 2017(5).[5] Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. [J]. Nature,2003 May 15;423(6937):337-42. [6] Delmas PD.Clinical potential of RANKL inhibition for the man-agement of postmenopausal osteoporosis and other metabolic bone diseases[J].J Clin Densitom,2008,11(2):325-338.[7] Lacey, D.L., et al., Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov, 2012. 11(5): p. 401-19.[8] Cummings SR,Martin JS, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med.2009;361(8):756–65.[9] Bone HG,Wagman RB,Brandi ML,et al.10 years of denosumab treatment in postmenopausal women with osteoporosis:results from the phase 3 randomised FREEDOM trial and open-label extension[J].Lancet Diabetes Endocrinol,2017,5:513-523.[10] LYU H, JUNDI B, XU C, et al. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials [J]. The Journal of clinical endocrinology and metabolism, 2019, 104(5): 1753-65.[11] McClung MR,Lewiecki EM,Cohen SB,et al. Denosumab in postmenopausal women with low bone mineral density[J].N Engl J Med,2006,354(8):821-831.[12] Peterson Mc, Stouch Bj, Martin Sw, et al. The pharmacokinetics of denosumab (AMG 162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass[J]. Bone Miner. Res. (2005) 20(Suppl. 1):S293.